Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Payments To Physicians Dropped 33% In 2015; Most Firms Saw Boost

This article was originally published in The Pink Sheet Daily

Executive Summary

Under CMS' Open Payments program, medical product manufacturers reported $7.52bn in payments and ownership and investment interests to physicians and teaching hospitals, up from $6.49bn in 2014.

You may also be interested in...



GSK Returns To Paid External Experts For Physician Communications

Policy update reverses approach announced in 2013 on the basis that physicians prefer peer-to-peer communications with global expert practitioners, firm explains.

AbbVie Hikes Doc Payments By 135%, Merck By 86% As BMS, J&J Cut Spending

Under CMS' Open Payments program, medical product manufacturers reported $8.1bn in payments and ownership and investment interests to physicians and teaching hospitals in 2016, a 1% increase from the previous year.

How To Deter Pharma Conflict Of Interests: Have FDA, CMS Grade Cost-Effectiveness

JAMA editorial suggests ways to reduce conflicts of interest in industry marketing; study shows restricting pharmaceutical detailing at academic medical centers led to 1.67% mean absolute reduction in market share of detailed drugs.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel